vs
ICU MEDICAL INC（ICUI）与RPC INC（RES）财务数据对比。点击上方公司名可切换其他公司
ICU MEDICAL INC的季度营收约是RPC INC的1.3倍（$540.7M vs $425.8M），RPC INC净利率更高（-0.7% vs -2.9%，领先2.2%），RPC INC同比增速更快（27.0% vs -14.1%），ICU MEDICAL INC自由现金流更多（$36.0M vs $31.2M），过去两年RPC INC的营收复合增速更高（6.2% vs -2.3%）
ICU医疗是总部位于美国加利福尼亚州圣克莱门特的医疗科技企业，专注于研发预防血流感染、保护医护人员免受传染病或危险药物侵害的医疗产品，产品线覆盖静脉治疗用品、输液泵、无针血管通路设备、定制输液套装、危险药物密闭处理系统、传感导管以及无针封闭式血液采样系统等。
RPC集团是总部位于英国的企业，曾是欧洲规模最大的塑料包装供应商之一，总部坐落于北安普敦郡的拉什登。该公司此前在伦敦证券交易所上市，2019年被贝瑞全球集团收购，贝瑞全球集团又于2025年被安海斯包装收购。
ICUI vs RES — 直观对比
营收规模更大
ICUI
是对方的1.3倍
$425.8M
营收增速更快
RES
高出41.1%
-14.1%
净利率更高
RES
高出2.2%
-2.9%
自由现金流更多
ICUI
多$4.7M
$31.2M
两年增速更快
RES
近两年复合增速
-2.3%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $540.7M | $425.8M |
| 净利润 | $-15.7M | $-3.1M |
| 毛利率 | 37.5% | 21.0% |
| 营业利润率 | 1.0% | -0.9% |
| 净利率 | -2.9% | -0.7% |
| 营收同比 | -14.1% | 27.0% |
| 净利润同比 | 34.0% | -124.0% |
| 每股收益（稀释后） | $-0.63 | $-0.02 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ICUIRES
| Q4 25 | $540.7M | $425.8M | ||
| Q3 25 | $537.0M | $447.1M | ||
| Q2 25 | $548.9M | $420.8M | ||
| Q1 25 | $604.7M | $332.9M | ||
| Q4 24 | $629.8M | $335.4M | ||
| Q3 24 | $589.1M | $337.7M | ||
| Q2 24 | $596.5M | $364.2M | ||
| Q1 24 | $566.7M | $377.8M |
净利润ICUIRES
| Q4 25 | $-15.7M | $-3.1M | ||
| Q3 25 | $-3.4M | $13.0M | ||
| Q2 25 | $35.3M | $10.1M | ||
| Q1 25 | $-15.5M | $12.0M | ||
| Q4 24 | $-23.8M | $12.8M | ||
| Q3 24 | $-33.0M | $18.8M | ||
| Q2 24 | $-21.4M | $32.4M | ||
| Q1 24 | $-39.5M | $27.5M |
毛利率ICUIRES
| Q4 25 | 37.5% | 21.0% | ||
| Q3 25 | 37.4% | 25.1% | ||
| Q2 25 | 37.9% | 24.5% | ||
| Q1 25 | 34.7% | 26.7% | ||
| Q4 24 | 36.1% | 25.4% | ||
| Q3 24 | 34.8% | 26.7% | ||
| Q2 24 | 34.8% | 28.0% | ||
| Q1 24 | 32.7% | 26.8% |
营业利润率ICUIRES
| Q4 25 | 1.0% | -0.9% | ||
| Q3 25 | 2.6% | 4.7% | ||
| Q2 25 | 1.9% | 3.7% | ||
| Q1 25 | 2.1% | 3.7% | ||
| Q4 24 | 6.0% | 3.1% | ||
| Q3 24 | 1.4% | 5.7% | ||
| Q2 24 | 1.3% | 9.7% | ||
| Q1 24 | -1.9% | 8.6% |
净利率ICUIRES
| Q4 25 | -2.9% | -0.7% | ||
| Q3 25 | -0.6% | 2.9% | ||
| Q2 25 | 6.4% | 2.4% | ||
| Q1 25 | -2.6% | 3.6% | ||
| Q4 24 | -3.8% | 3.8% | ||
| Q3 24 | -5.6% | 5.6% | ||
| Q2 24 | -3.6% | 8.9% | ||
| Q1 24 | -7.0% | 7.3% |
每股收益（稀释后）ICUIRES
| Q4 25 | $-0.63 | $-0.02 | ||
| Q3 25 | $-0.14 | $0.06 | ||
| Q2 25 | $1.43 | $0.05 | ||
| Q1 25 | $-0.63 | $0.06 | ||
| Q4 24 | $-0.97 | $0.06 | ||
| Q3 24 | $-1.35 | $0.09 | ||
| Q2 24 | $-0.88 | $0.15 | ||
| Q1 24 | $-1.63 | $0.13 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | — | $210.0M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $2.1B | $1.1B |
| 总资产 | $4.1B | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资ICUIRES
| Q4 25 | — | $210.0M | ||
| Q3 25 | — | $163.5M | ||
| Q2 25 | — | $162.1M | ||
| Q1 25 | — | $326.7M | ||
| Q4 24 | $308.6M | $326.0M | ||
| Q3 24 | $312.5M | $276.9M | ||
| Q2 24 | $302.6M | $261.5M | ||
| Q1 24 | $251.4M | $212.2M |
股东权益ICUIRES
| Q4 25 | $2.1B | $1.1B | ||
| Q3 25 | $2.1B | $1.1B | ||
| Q2 25 | $2.1B | $1.1B | ||
| Q1 25 | $2.0B | $1.1B | ||
| Q4 24 | $2.0B | $1.1B | ||
| Q3 24 | $2.0B | $1.1B | ||
| Q2 24 | $2.0B | $1.1B | ||
| Q1 24 | $2.1B | $1.0B |
总资产ICUIRES
| Q4 25 | $4.1B | $1.5B | ||
| Q3 25 | $4.1B | $1.5B | ||
| Q2 25 | $4.1B | $1.5B | ||
| Q1 25 | $4.2B | $1.3B | ||
| Q4 24 | $4.2B | $1.4B | ||
| Q3 24 | $4.3B | $1.3B | ||
| Q2 24 | $4.3B | $1.3B | ||
| Q1 24 | $4.3B | $1.3B |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $60.6M | $61.9M |
| 自由现金流经营现金流 - 资本支出 | $36.0M | $31.2M |
| 自由现金流率自由现金流/营收 | 6.6% | 7.3% |
| 资本支出强度资本支出/营收 | 4.6% | 7.2% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | $91.8M | $52.9M |
8季度趋势，按日历期对齐
经营现金流ICUIRES
| Q4 25 | $60.6M | $61.9M | ||
| Q3 25 | $56.7M | $46.5M | ||
| Q2 25 | $11.2M | $53.1M | ||
| Q1 25 | $51.3M | $39.9M | ||
| Q4 24 | $40.2M | $94.2M | ||
| Q3 24 | $36.1M | $70.7M | ||
| Q2 24 | $82.0M | $127.9M | ||
| Q1 24 | $45.8M | $56.6M |
自由现金流ICUIRES
| Q4 25 | $36.0M | $31.2M | ||
| Q3 25 | $27.6M | $4.1M | ||
| Q2 25 | $-8.5M | $10.0M | ||
| Q1 25 | $36.7M | $7.6M | ||
| Q4 24 | $16.1M | $53.7M | ||
| Q3 24 | $16.2M | $19.1M | ||
| Q2 24 | $62.5M | $52.9M | ||
| Q1 24 | $29.9M | $3.8M |
自由现金流率ICUIRES
| Q4 25 | 6.6% | 7.3% | ||
| Q3 25 | 5.1% | 0.9% | ||
| Q2 25 | -1.5% | 2.4% | ||
| Q1 25 | 6.1% | 2.3% | ||
| Q4 24 | 2.6% | 16.0% | ||
| Q3 24 | 2.7% | 5.6% | ||
| Q2 24 | 10.5% | 14.5% | ||
| Q1 24 | 5.3% | 1.0% |
资本支出强度ICUIRES
| Q4 25 | 4.6% | 7.2% | ||
| Q3 25 | 5.4% | 9.5% | ||
| Q2 25 | 3.6% | 10.2% | ||
| Q1 25 | 2.4% | 9.7% | ||
| Q4 24 | 3.8% | 12.1% | ||
| Q3 24 | 3.4% | 15.3% | ||
| Q2 24 | 3.3% | 20.6% | ||
| Q1 24 | 2.8% | 14.0% |
现金转化率ICUIRES
| Q4 25 | — | — | ||
| Q3 25 | — | 3.59× | ||
| Q2 25 | 0.32× | 5.23× | ||
| Q1 25 | — | 3.31× | ||
| Q4 24 | — | 7.38× | ||
| Q3 24 | — | 3.76× | ||
| Q2 24 | — | 3.95× | ||
| Q1 24 | — | 2.06× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ICUI
| Infusion Consumables | $284.7M | 53% |
| Infusion Systems | $176.3M | 33% |
| Vital Care | $79.7M | 15% |
RES
| Technical Service | $405.2M | 95% |
| Other | $8.8M | 2% |
| Nitrogen | $6.6M | 2% |
